Improved overall survival in metastatic breast cancer - CLEOPATRA

November 11, 2014

 

Overall survival was significantly improved by the administration of first-line pertuzumab, trastuzumab and docetaxel in the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) study.

Read more at:

http://www.esmo.org/Conferences/ESMO-2014-Congress/News-Articles/Final-Overall-Survival-Analysis-from-the-CLEOPATRA-Study-in-Patients-with-HER2-Positive-Metastatic-Breast-Cancer

 
Tags:
metastatic breast cancer
monoclonal antibodies
Back to news